Detalles de la búsqueda
1.
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
Cancer
; 118(17): 4139-47, 2012 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22180287
2.
Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.
Pain Med
; 13(11): 1417-24, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23110676
3.
Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.
Sci Transl Med
; 13(621): eabg2612, 2021 11 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34818059
4.
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
J Clin Oncol
; 21(7): 1232-7, 2003 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12663709
5.
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
J Clin Oncol
; 22(6): 1025-33, 2004 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15020604
6.
Effects of a mammography decision-making intervention at 12 and 24 months.
Am J Prev Med
; 22(4): 247-57, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-11988381
7.
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
J Clin Oncol
; 32(7): 671-7, 2014 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24449231
8.
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
J Clin Oncol
; 31(31): 3944-50, 2013 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24101043
9.
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
J Natl Cancer Inst
; 105(22): 1729-37, 2013 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24136890
10.
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
J Clin Oncol
; 30(13): 1534-40, 2012 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22454414
11.
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
Cancer
; 117(3): 526-33, 2011 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20862750
12.
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
J Natl Cancer Inst
; 102(13): 942-9, 2010 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-20554945
13.
Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.
Cancer
; 101(2): 370-8, 2004 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15241836
14.
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
Cancer
; 94(3): 665-72, 2002 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11857298
Resultados
1 -
14
de 14
1
Próxima >
>>